Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy
Authors:
- 21 August 2009
- journal article
- case report
- Published by Springer Nature in Rheumatology International
- Vol. 30 (11) , 1503-1505
Abstract
Intravenous immunoglobulin (IVIg) is emerging as the mainstay in the treatment of many autoimmune diseases, including systemic lupus erythematosus. IVIg has been found to be beneficial in myocarditis due to dermatomyositis/polymyositis, Kawasaki disease, and viral myocarditis in children. We report an 18-year-old man of active lupus with worsening cardiac systolic function who did not respond to pulse methylprednisolone and cyclophosphamide, but subsequently showed an improvement in his cardiac function after IVIg administration.Keywords
This publication has 14 references indexed in Scilit:
- What is the contents of the magic draft IVIg?Autoimmunity Reviews, 2008
- Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patientsAnnals of the Rheumatic Diseases, 2007
- Four Cases of Kawasaki Syndrome Complicated With MyocarditisCirculation Journal, 2006
- Myocarditis as an initial manifestation of systemic lupus erythematosus.2004
- IgG Fc ReceptorsAnnual Review of Immunology, 2001
- Cardiac Involvement in Systemic Lupus ErythematosusMayo Clinic Proceedings, 1999
- Immunomodulation of various autoimmune diseases by intravenous immunoglobulinDrugs of Today, 1999
- Gamma-globulin treatment of acute myocarditis in the pediatric population.Circulation, 1994
- Intravenous immunoglobulin therapy in systemic lupus erythematosus‐associated thrombocytopeniaArthritis & Rheumatism, 1990
- The Myocarditis of Systemic Lupus ErythematosusAnnals of Internal Medicine, 1978